Keyword: Voyager Therapeutics
Four months after Voyager's chief and founder said he would step down, the neurological disease biotech has found a new leader.
AbbVie has teamed with Voyager Therapeutics on a tau protein-targeting program, paying $69 million for an option on the Alzheimer’s disease candidate.
Bob Hugin retires from Celgene, Voyager founder steps down as CEO, Boehringer named new U.S. chief to replace retiring Fonteyne.
Voyager Therapeutics’ chief and founder Steven Paul, M.D., is stepping down to become an “executive science advisor.”
The pact will see UCL work with Synpromics on synthetic gene promoters that enable highly specific gene therapies.
The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global phase 2/3 trial.
Wednesday's shot of your news of note.
Shares in Voyager Therapeutics jumped 35% in after-hours trading on the back of interim data from an early trial of its Parkinson’s disease gene therapy.